1. Scrip

Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine

Trial Start Expected In August-October

 
• By Vibha Ravi

Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.

Biochemistry
Vaccine Has Part Of SARS-CoV-2 Spike Protein Coding Region Added To M2SR • Source: Shutterstock

Bharat Biotech International Ltd., one of India's leading vaccine makers, has partnered with the University of Wisconsin–Madison (UW-Madison) and US-based vaccine company FluGen Inc. to develop a COVID-19 vaccine, joining the ranks of those working to provide nations with armor to tackle the coronavirus infection.

Like several other drugs and vaccines currently being developed to combat COVID-19 respiratory disease, this candidate is also repurposed, using a platform originally developed for a flu vaccine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.